| Date | Title | Description |
| 11.03.2024 | Aderans Co., Ltd. Signed an exclusive license agreement for hair regeneration intellectual property rights with Stemson (USA), which conducts hair growth research using iPS cells. | Aderans Co., Ltd.
Signed an exclusive license agreement for hair regeneration
intellectual property rights with Stemson Inc. (USA), which conducts hair growth research using iPS cells.
……
Aderans Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo... |
| 11.03.2024 | Aderans Co., Ltd. Signed an exclusive license agreement for hair regeneration intellectual property rights with Stemson (USA), which conducts hair growth research using iPS cells. | - |
| 19.08.2022 | Meet Jenny Rooke, founder and Managing Partner at Genoa Ventures | Genoa Ventures invests at the intersection of biology and technology
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there are more startups than ... |
| 01.12.2021 | Qualigen Therapeutics : Announces Closing of $8.82 Million Registered Direct Offering - Form 8-K | Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct Offering
CARLSBAD, Calif. (December 1, 2021) - Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered di... |
| 24.11.2021 | Seelos Therapeutics : Agreement Includes the Option of up to an Additional $30 Million of Funding Contingent on Achievement of Certain Milestones - Form 8-K | - Agreement Includes the Option of up to an Additional $30 Million of Funding Contingent on Achievement of Certain Milestones
NEW YORK, Nov 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutica... |
| 18.10.2021 | Axsome Therapeutics : Expands Term Loan Facility with Hercules Capital to $300 Million | $100 million now available upon the potential FDA approval of AXS-05
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central ... |
| 18.10.2021 | Axsome Therapeutics : Expands Term Loan Facility with Hercules Capital to $300 Million $100 million now available upon the potential FDA approval of AXS-05 - Form 8-K | Axsome Therapeutics Expands Term Loan Facility with Hercules Capital to $300 Million
$100 million now available upon the potential FDA approval of AXS-05
NEW YORK, October 18, 2021 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM)... |
| 07.10.2021 | AffyImmune Therapeutics : Announces $30M Series A+ Financing from ORI Capital | NATICK, Mass., Oct. 7, 2021 /PRNewswire/ -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company developing and deploying its Tune & Track platform for the use of CAR T cells to treat solid tumors, announced today the c... |
| 23.09.2021 | Garuda Therapeutics : Launches with $72 Million Series A Financing | Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies, launched today with an oversubscribed $72 million Series A financing led by Aisling Capital, Northpond Ventures and Orbimed, supported by Cormorant As... |
| 21.09.2021 | 858 Therapeutics : Launches with Proven Team and $60 Million Series A Financing | 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital. Proceeds are being used to develop a port... |
| 19.08.2021 | Guided Therapeutics : Receives Notification of Successful Clinical Trial Regulatory Review and $133,000 Payment from China | Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva® Advanced Cervical Scan, based on its patented biophotonic technology, announced today it had passed the regulatory compliance review at the Department of Obstetrics & Gyn... |
| 18.08.2021 | Ranok Therapeutics : Secures $40 Million Series B Financing to Advance its Innovative Targeted Protein Degradation Pipeline | Ranok Therapeutics (Hangzhou) Co. Ltd., an emerging biopharmaceutical company focused on developing breakthrough therapies for cancer and other serious diseases, today announced it had secured a $40 million Series B funding round denominate... |
| 20.07.2021 | Digital health news, funding roundup in the prior week; July 18 | With $150B already invested, VC is set to have another recording breaking year
With $150B already invested, VC is set to have another recording breaking year. There was $75 billion invested across an estimated 4,302 deals in the second quar... |
| 16.07.2021 | AbbVie-backed Stemson snags $15M series A for hairy brush-up with Rogaine, Propecia | AbbVie wants more people to regain the pleasure of going to a barbershop or local hair salon, and the biopharma has a keen eye for aesthetics. So, it's backing Stemson Therapeutics as part of a $15 million series A, disclosed Thursday.
Afte... |
| 16.07.2021 | Daily funding roundup - July 16th, 2021 | Shopmonkey raised $75M; Daloopa landed $20M; Stemson Therapeutics secured $15M; Halla picks up $4.5M
Netradyne: Netradyne is a San Diego-based startup that uses cameras and edge computing to improve commercial driver safety. Netradyne has r... |
| 15.07.2021 | Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss | Did you miss today's livestream? Watch the AI at the Edge & IoT Summit on demand now.
DCVC Bio leads round advancing new breakthrough hair regeneration technology to help millions suffering the physical and mental effects of hair loss
S... |
| 15.07.2021 | Stemson Therapeutics Secures $15M Series A Funding to Cure Hair Loss | DCVC Bio leads round advancing new breakthrough hair regeneration technology to help millions suffering the physical and mental effects of hair loss
SAN DIEGO–(BUSINESS WIRE)–July 15, 2021–
Stemson Therapeutics announced today the closing o... |
| 15.07.2021 | Stemson Therapeutics : Secures $15M Series A Funding to Cure Hair Loss | Stemson Therapeutics announced today the closing of a DCVC Bio-led $15 million Series A financing to advance development of Stemson’s proprietary therapeutic solution to cure hair loss. Genoa Ventures, AbbVie Ventures and other investors jo... |
| 15.07.2021 | Stemson Therapeutics Raises $15M in Series A Funding | Stemson Therapeutics, a San Diego, CA-based pre-clinical stage cell therapy company, closed a $15m Series A financing.
The round was led by DCVC Bio with participation from Genoa Ventures, AbbVie Ventures and other investors. In addition, K... |
| 15.07.2021 | AbbVie-backed Stemson snags $15M series A for hairy brush-up with Rogaine, Propecia | AbbVie wants more people to regain the pleasure of going to a barbershop or local hair salon, and the biopharma has a keen eye for aesthetics. So, it's backing Stemson Therapeutics as part of a $15 million series A, disclosed Thursday.
Hair... |
| 15.07.2021 | Stemson Therapeutics gains $15M in Series A funding to further develop their therapeutic solution that cures hair loss | - |
| 02.07.2021 | PANBELA THERAPEUTICS : ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK (Form 8-K) | PANBELA THERAPEUTICS ANNOUNCES $5.0 MILLION BOUGHT DEAL OFFERING OF COMMON STOCK
MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA) (the 'Company' or 'Panbela'), a clinical stage biopharmaceutical compa... |
| 23.06.2021 | Orum Therapeutics : Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads into Clinical Trials for Cancer | Orum Therapeutics, a biotech company pioneering the development of targeted protein degraders to treat cancer, today announced the close of a $84 million Series B financing. This includes a previously announced $30 million financing and $54... |
| 17.06.2021 | PanTher Therapeutics : Closes Oversubscribed $5.4M Series A Round, Expands Board of Directors, As Company Prepares to Initiate First Clinical Trial of Novel Localized Treatment of Pancreatic Cancer | PanTher Therapeutics (PanTher), a privately held oncology company revolutionizing the treatment of solid tumors through direct, localized, and sustained delivery of proven and novel therapeutic agents, announces today that it has closed an ... |
| 03.06.2021 | CANNTAB THERAPEUTICS LIMITED
Canntab Therapeutics : Announces the Early Exercise of $1,259,250 Warrants | TORONTO, June 3, 2021 /PRNewswire/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for th... |
| 03.06.2021 | CANNTAB THERAPEUTICS LIMITED
Canntab Therapeutics : Announces the Early Exercise of $1,259,250 Warrants | TORONTO, June 3, 2021 /CNW/ - Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeut... |
| 03.06.2021 | Stablix Therapeutics : Launches with $63 Million Series A Financing | Stablix Therapeutics, a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS), today announced a $63 million Series A financing led by founding investor Versant Ventures together with NEA, Cormorant, Euclidean C... |
| 25.05.2021 | HERON THERAPEUTICS, INC.
Heron Therapeutics : Announces $150 Million Convertible Debt Financing | SAN DIEGO, May 25, 2021 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron") today announced that it has sold $150 million of senior unsecured convertible promissory notes (the "Notes") in a private placemen... |
| 20.05.2021 | SEELOS THERAPEUTICS, INC.
Seelos Therapeutics : Announces Pricing of $60 Million Public Offering of Common Stock | NEW YORK, May 20, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders and rare diseases, announced toda... |
| 06.05.2021 | CARDIOL THERAPEUTICS INC.
Cardiol Therapeutics : Announces $15 Million Bought Deal Public Offering | Oakville - Cardiol Therapeutics Inc. (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage biotechnology company focused on developing innovative anti- inflammatory therapies for the treatment of cardiovascular disease, is pleased to a... |
| 31.03.2021 | Guided Therapeutics : Closes $2.114 Million Series F Preferred Stock Financing | Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had closed its Series F Preferred Stock Financing on March 26, 2021. This over... |
| 31.03.2021 | GUIDED THERAPEUTICS, INC.
Guided Therapeutics : Closes $2.114 Million Series F Preferred Stock Financing | Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it had closed its Series F Preferred Stock Financing on March 26, 2021. This over... |
| 30.03.2021 | AffaMed Therapeutics : Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline | SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders... |
| 25.03.2021 | WINDTREE THERAPEUTICS, INC.
Windtree Therapeutics : Announces Closing of $30.0 Million Public Offering | WARRINGTON, Pa., March 25, 2021 /PRNewswire/ -- Windtree Therapeutics, Inc. (NasdaqCM: WINT) ("Windtree" or the "Company"), a biotechnology and medical device company focused on advancing multiple late-stage intervention... |
| 16.02.2021 | Guided Therapeutics : Raises US $1.1 Million in New Preferred Stock Offering | Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of a rapid and painless testing platform based on its patented biophotonic technology, announced today that it has thus far raised a total of US $1.1 million under the terms of a Series F P... |
| 16.10.2020 | ALTERITY THERAPEUTICS LIMITED
Alterity Therapeutics : raises $35M in placement to international and Australian institutions and sophisticated investors. | Successfully obtained binding commitments for A$35M via institutional placement to be settled in 2 tranches
Tranche 1: $10M raised under Alterity's current placement capacity
Tranche 2: $25M subject to shareholder approval
Attached 1.1 opti... |
| 21.09.2020 | Hair Regeneration Therapy Company Stemson Therapeutics Raises $7.5 Million | Stemson Therapeutics announced that it has raised a $7.5 million seed round of funding led by Allergan Aesthetics (an AbbVie Company) and impact investor Fortunis Capital to advance the development of Stemson’s therapeutic solution to cure ... |
| 18.09.2020 | Stemson Therapeutics Secures $7.5M in Seed Financing | Stemson Therapeutics, a San Diego, CA-based maker of a therapeutic solution to cure hair loss, raised $7.5m in seed financing.
The round was led by Allergan Aesthetics, an AbbVie Company, and impact investor Fortunis Capital.
Stemson aims t... |
| 17.09.2020 |
Stemson Therapeutics Finds $7.5M For Hair Loss Cure
| San Diego-based Stemson Therapeutics, a startup working on therapies to cure hair loss, has raised $7.5M in a seed funding round. The funding came from Allergan Aethetics and Fortunis Capital. According to the company, the new funding will ... |
| 17.09.2020 | San Diego’s Stemson Therapeutics raises US$ 7.5M in Seed Round | - |
| 16.09.2020 | Stemson Therapeutics Inks $7.5M Seed Round |
SAN DIEGO, CA, Stemson Therapeutics announced today a $7.5 million seed financing led by Allergan Aesthetics.
>> Click here for more funding data on Stemson Therapeutics
>> To export Stemson Therapeutics funding data to PDF ... |
| 16.09.2020 | Stemson Therapeutics has announced their $7.5M Seed raise to continue developing their breakthrough hair regeneration therapy to cure hair loss | - |
